Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raptiva in moderate to severe plaque psoriasis
NCT00109317Phase 3Completed
- Sponsor
- Genentech
- Start
- Sep 2002
01
Overview
A Phase 3 trial of efalizumab in plaque psoriasis, sponsored by Genentech. Started Sep 2002; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00109317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109317.